Oxaliplatin Injection, Solution
Product Images NDC 68001-468

8 FDA label images from Bluepoint Laboratories · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 68001-468). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Oxaliplatin 01)

Structure (Oxaliplatin 01)
Chemical structure of oxaliplatin showing the platinum atom coordinated with a cyclohexane diamine ligand and oxalate groups.*
FDA Label Image

Figure 1 (Oxaliplatin 02)

Figure 1 (Oxaliplatin 02)
A line graph comparing disease-free survival (DFS) probability over time (months) for two treatment arms, FOLFOX4 and LV5FU2. The graph includes a legend, event numbers with percentages, hazard ratio with 95% confidence interval, a p-value from a stratified logrank test, and the number of patients at risk over time for each arm.*
FDA Label Image

Figure 2 (Oxaliplatin 03)

Figure 2 (Oxaliplatin 03)
A line graph depicting disease-free survival (DFS) probability over time in months (0 to 72). Two treatment arms, FOLFOX4 and LV5FU2, both with DUKES C stage, are compared with DFS probability on the vertical axis (0.0 to 1.0). Statistical data including a hazard ratio and logrank test p-value are displayed within the graph.*
FDA Label Image

Figure 3 (Oxaliplatin 04)

Figure 3 (Oxaliplatin 04)
A survival curve graph illustrating the percentage of patients surviving over 24 months for three treatment groups: Oxaliplatin Injection USP plus 5-FU/LV, Oxaliplatin Injection USP plus irinotecan, and Irinotecan plus 5-FU/LV. The graph shows median survival times in months for each group, with survival percentage on the vertical axis and time in months on the horizontal axis.*
FDA Label Image

Vial Container Label 50mg/10ml Rev 02/2025 (Oxaliplatin Injection Usp 50mg 10ml Vial Label Rev 0225)

Vial Container Label 50mg/10ml Rev 02/2025 (Oxaliplatin Injection Usp 50mg 10ml Vial Label Rev 0225)
Label for Oxaliplatin injection USP 50 mg/10 mL (5 mg/mL) intravenous solution. The sterile aqueous, preservative-free solution is supplied in a 10 mL single-dose vial. The label includes cautions about cytotoxicity, storage instructions, and manufacturer details for BluePoint Laboratories, with barcode and NDC 68001-468-36.*
FDA Label Image

Oxaliplatin Injection Usp 50mg/10ml Carton Label Rev 02/2025 (Oxaliplatin Injection Usp 50mg 10ml Carton Rev 0225)

Oxaliplatin Injection Usp 50mg/10ml Carton Label Rev 02/2025 (Oxaliplatin Injection Usp 50mg 10ml Carton Rev 0225)
Packaging label for Oxaliplatin Injection, USP 50 mg per 10 mL (5 mg/mL) solution for intravenous use, labeled by BluePoint Laboratories. The label includes dosage and administration cautions, barcode, NDC 68001-468-36, and storage instructions. The package is a single-dose vial with warnings about cytotoxicity and proper handling of sodium chloride-containing solutions.*
FDA Label Image

Oxaliplatin Injection Usp 100mg_20ml Vial Container Label Rev 02/2025 (Oxaliplatin Injection Usp 100mg 20ml Vial Label Rev 0225)

Oxaliplatin Injection Usp 100mg_20ml Vial Container Label Rev 02/2025 (Oxaliplatin Injection Usp 100mg 20ml Vial Label Rev 0225)
Oxaliplatin Injection USP 100 mg/20 mL (5 mg/mL) in a 20 mL single-dose vial for intravenous use. The label specifies sterile aqueous solution, preservative-free, and cautions that it contains a cytotoxic agent. Manufactured by Qilu Pharmaceutical (Hainan) Co., Ltd. for BluePoint Laboratories. Additional storage and usage instructions are included, with a barcode on the right side.*
FDA Label Image

Oxaliplatin Injection Usp 100mg_20ml Carton Label Rev 02/2025 (Oxaliplatin Injection Usp 100mg 20ml Carton Rev 0225)

Oxaliplatin Injection Usp 100mg_20ml Carton Label Rev 02/2025 (Oxaliplatin Injection Usp 100mg 20ml Carton Rev 0225)
Packaging label for Oxaliplatin Injection, USP 100 mg/20 mL (5 mg/mL) solution for intravenous use by BluePoint Laboratories. The label includes dosing strength, route (IV), cautions about cytotoxicity, storage instructions, and warnings such as not mixing with sodium chloride solutions. The product is packaged as a single-dose vial. The label features the BluePoint logo and necessary regulatory and batch information areas.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.